CAC
ADMA icon

Certified Advisory Corp’s ADMA Biologics ADMA Stock Holding History

Certified Advisory Corp’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$2K – 217
2021
Q1 		$2K Buy
+1,000
New +$2.29K ﹤0.01% 724
2020
Q2 		$29K Buy
+10,000
New +$28.7K 0.01% 380

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Certified Advisory Corp's ADMA Position: Q2 2021 in Review

Certified Advisory Corp sold out of ADMA Biologics (ADMA) in Q2 2021, closing a stake of 1,000 shares — an estimated $2K sold.

Certified Advisory Corp first reported a position in ADMA in Q2 2020 and held it in 2 quarters. The position peaked at $29K in Q2 2020. 90 funds tracked by Wall St. Rank hold ADMA as of Q2 2021.

  • Certified Advisory Corp reported no remaining ADMA Biologics position as of Q2 2021 after selling out during the quarter.
  • Certified Advisory Corp sold 1,000 ADMA Biologics shares in Q2 2021, an estimated $2K.
  • Certified Advisory Corp first reported a position in ADMA Biologics in Q2 2020 and held it in 2 quarters.
  • Certified Advisory Corp's ADMA Biologics position peaked at $29K in Q2 2020.
  • 90 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2021.

Based on Certified Advisory Corp's 13F filing for Q2 2021, filed 16 Aug 2021.